-European Commission Decision Anticipated in Approximately Two Months- DURHAM, N.C. --(BUSINESS WIRE)--Nov. 13, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 10, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
Year-to-Date Net Revenues of $58.5 Million Increased 29% over 2019 Third Quarter Net Revenues of $20.1 Million or $77 Per Bottle U.S. Dry Eye Trial Initiated and Japanese Glaucoma Trial Set to Commence Conference Call and Webcast Today, November 5 th , at 5:00 p.m. ET DURHAM, N.C.
-First Patient Dosed in 90-Day Efficacy Trial Named COMET-1- DURHAM, N.C. --(BUSINESS WIRE)--Oct. 29, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
